Answers are grounded in this paper and cite their sources.
An increasing number of European countries use pharmacoeconomic evaluations of innovative medicines in their pricing and reimbursement decisions, e.g. France, the Netherlands, Belgium, U.K., Sweden and Germany. These studies may be conducted by using
No takes yet. Share an insight, caveat, or question.
Marcus Oehlrich (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: